Allelic ratio of KRAS mutations in pancreatic cancer
KRAS is not simply mutated or wild type in pancreatic ductal adenocarcinoma (PDAC); actually, it has never been. More than 90% of PDACs carry mutated KRAS alleles; however, the impact on PDAC biology may vary with the tumor-specific allelic ratio and dosage of mutated KRAS.
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) Editorial |
| Language: | English |
| Published: |
16 March 2015
|
| In: |
The oncologist
Year: 2015, Volume: 20, Issue: 4, Pages: e8-e9 |
| ISSN: | 1549-490X |
| DOI: | 10.1634/theoncologist.2014-0408 |
| Online Access: | Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.1634/theoncologist.2014-0408 Verlag, lizenzpflichtig, Volltext: https://theoncologist.onlinelibrary.wiley.com/doi/abs/10.1634/theoncologist.2014-0408 
|
| Author Notes: | Jochen K. Lennerz, Albrecht Stenzinger |
| Summary: | KRAS is not simply mutated or wild type in pancreatic ductal adenocarcinoma (PDAC); actually, it has never been. More than 90% of PDACs carry mutated KRAS alleles; however, the impact on PDAC biology may vary with the tumor-specific allelic ratio and dosage of mutated KRAS. |
|---|---|
| Item Description: | Gesehen am 17.06.2020 |
| Physical Description: | Online Resource |
| ISSN: | 1549-490X |
| DOI: | 10.1634/theoncologist.2014-0408 |